什麼是~~~DECA？

什麼是Decapeptyl？10.7
Gynecology and Obstetrics, Johns Hopkins Medical Institution, Baltimore, MD; Muasher Center for Fertility and IVF, Fairfax, VA


GnRH-agonist administration in the mid-luteal phase yields favorable pregnancy and implantation rates in stimulated in vitro fertilization cycles with GnRH-antagonist

Z.R. Hubayter, A. Rettberg, A. Ibrahim, H. Zacur, J. Garcia, S.J. Muasher
P-763

Article Outline

• Copyright
OBJECTIVE: Our goal was to assess a novel role for GnRH-agonist as a supplement in luteal phase. GnRH-agonist receptors are present in the endometrium and the ovaries. Furthermore, the corpus luteum function may improve with GnRH-agonist induced endogenous flare with pituitary hormones. In vitro, GnRH-agonists have improved mouse embryo developement. Recent studies have demonstrated improved implantation rate with the use of a single dose GnRH-agonist 6 days after oocyte retreival in an IVF cycle (Tesarik, Hum Reprod, 2006,21: 2572-9). Our objective was to evaluate the impact of a daily GnRH-agonist at the time of implantation (Days 5-7 following retreival) on IVF outcomes in antagonist cycles.


GnRH-agonist administration in the mid-luteal phase yields favorable pregnancy and implantation rates in stimulated in vitro fertilization cycles with GnRH-antagonist

Z.R. Hubayter, A. Rettberg, A. Ibrahim, H. Zacur, J. Garcia, S.J. Muasher
P-763

Article Outline

• Copyright
OBJECTIVE: Our goal was to assess a novel role for GnRH-agonist as a supplement in luteal phase. GnRH-agonist receptors are present in the endometrium and the ovaries. Furthermore, the corpus luteum function may improve with GnRH-agonist induced endogenous flare with pituitary hormones. In vitro, GnRH-agonists have improved mouse embryo developement. Recent studies have demonstrated improved implantation rate with the use of a single dose GnRH-agonist 6 days after oocyte retreival in an IVF cycle (Tesarik, Hum Reprod, 2006,21: 2572-9). Our objective was to evaluate the impact of a daily GnRH-agonist at the time of implantation (Days 5-7 following retreival) on IVF outcomes in antagonist cycles.

DESIGN: Retrospective analysis.
DESIGN: Retrospective analysis.

CONCLUSIONS: Mid luteal phase support with GnRH-agonist, around the days of implantation appears to yield favorable outcomes in IVF cycles using GnRH-antagonists for ovarian stimulation. A large randomized prospective controlled trial will need to be conducted in order to confirm these findings.

Gynecology and Obstetrics, Johns Hopkins Medical Institution, Baltimore, MD; Muasher Center for Fertility and IVF, Fairfax, VA
Supported by: None.

PII: S0015-0282(08)02718-0

doi:10.1016/j.fertnstert.2008.07.1347

© 2008 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Table 1. IVF outcome with GnRH-agonist luteal supplementation
Parameter Mean (SD)
Age (years) 34.7 (4.4)
Day 3 FSH (IU/L) 7.9 (2.2)
Peak estradiol (pg/ml)1664 (957)
Embryos transferred (n)3.0 (0.8)
Pregnancy rate / transfer55%
Implantation rate 28%
Miscarriage rate 11%

Category:

People & Blogs

Tags:

• 什麼是Decapeptyl？